ROCKVILLE, Md.--(BUSINESS WIRE)--BIOQUAL, Inc. (OTC Pink: BIOQ):
| Six Months Ended November 30, | Three Months Ended November 30, | |||||||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||||||
| Revenue | $ | 18,648,523 | $ | 14,602,623 | $ | 9,482,331 | $ | 8,004,826 | ||||||||
| Income Before Income Tax | $ | 3,489,749 | $ | 1,590,901 | $ | 1,759,360 | $ | 1,196,119 | ||||||||
| Net Income | $ | 2,015,349 | $ | 918,601 | $ | 1,016,160 | $ | 690,619 | ||||||||
| Basic Earnings per Share of Common Stock | $ | 2.26 | $ | 1.03 | $ | 1.14 | $ | .77 | ||||||||
| Diluted Earnings per Share of Common Stock | $ | 2.26 | $ | 1.03 | $ | 1.14 | $ | .77 | ||||||||
| Weighted Average Number of Shares Outstanding For Basic Earnings | 893,416 | 893,466 | 893,416 | 893,466 | ||||||||||||
| Weighted Average Number of Shares Outstanding For Diluted Earnings | 893,416 | 893,466 | 893,416 | 893,466 | ||||||||||||
For more detail related to the fiscal year 2017 unaudited second quarter results, please visit our web site at www.bioqual.com.
Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts and obtain new contracts; the Company’s ability to obtain new commercial contracts; the performance of the business acquired in the ABL acquisition; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual cost incurred in performing its contracts and the Company’s ability to manage its costs; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
Contacts
BIOQUAL, Inc.
Mark G. Lewis, Ph.D., CEO, 240-404-7654
